60 likes | 146 Vues
A Descriptive Overview & Upstream Considerations. Presented by: Michael Allen Daniel Demsey Avanthi Williams. Regulatory Considerations. Process Definition Scrutinized by regulatory authorities for safety and reliability Product Consistency
E N D
A Descriptive Overview&Upstream Considerations Presented by: Michael Allen Daniel Demsey Avanthi Williams
Regulatory Considerations • Process Definition • Scrutinized by regulatory authorities for safety and reliability • Product Consistency • Minimal variance in biochemical properties of product
Regulatory Considerations • Cell Lineage • Origin of cell line • Health of donor • Recombination methods used (viral vectors) • Cell Line Stability • Across number of generations from cell bank to finished product
Cell Line Selection Criteria • Capability to produce high product titers in the selected manufacturing process • Ability to produce a consistent product with uniform characteristics • Speed at which a high yielding cell line can be obtained
Potential Cell Lines • Murine Hybridoma • Human Anti-Mouse Antibody (HAMA) response • Recombinant Mouse Cells • Transformed Human Cells • EBV-transformed human lymphoblastoid cells used to produce the anti-D antibody • Prevents hemolytic disease in infants Tumour cell Antigen Antibody-producing cloned hybridomas Monoclonal antibodies Isolated/immunized antibody-forming cell Hybridomas
Cell Banking • Master Cell Bank (MCB) • Cryopreservation • Enough for life of process • Working Cell Bank (WCB) • Cryopreservation • Made from MCB Inoculate